Guidelines for Good Pharmacoepidemiology Practices

Chinese Journal of Pharmacovigilance ›› 2011, Vol. 8 ›› Issue (4): 252-256.

Guidelines for Good Pharmacoepidemiology Practices

RENJing-tian, WANGBo(Translation), LI Li-ming(Proofreading)

Received:2015-08-27 Revised:2015-08-27 Online:2011-04-10 Published:2015-08-27

Abstract

CLC Number:

R954

RENJing-tian, WANGBo(Translation), LI Li-ming(Proofreading). Guidelines for Good Pharmacoepidemiology Practices[J]. Chinese Journal of Pharmacovigilance, 2011, 8(4): 252-256.

[1]	JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
[2]	GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe. Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5.
[3]	MA Li’na, HU Xiaozhen, ZHENG Changhui, SUN Ying, ZHAO Xu, CAO Junling, XIAO Xiaohe. Visual analysis of knowledge map of toxic Chinese medicine Changshan toxicity-effect transformation based the thought of “yin du wei neng” [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 25-32.
[4]	WU Yunxiao, YU Yuelin, WANG Shengfeng, SUN Feng, MENG Ruogu, ZHAN Siyan. Suitability assessment of real-world data in active post-marketing surveillance of vaccine safety [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1081-1089.
[5]	JIA Jinsheng, WANG Qing, LIU Hongliang, HOU Yongfang. Evaluation index system of MAH pharmacovigilance work [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1090-1094.
[6]	LIU Hongliang, WANG Qing, HOU Yongfang. Design and implementation of polypharmacy risk data management platform for common diseases of the elderly based on real world data [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1095-1098.
[7]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
[8]	SHEN Yanjie, WU Yiqing. Management of adverse events during clinical trials [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 982-986.
[9]	LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue. Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.
[10]	ZHANG Yuqi, XU Xinyi, ZHU Lan, ZHU Yan. Comparison standard terminology for pharmaceutical dose forms [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 904-910.
[11]	ZHAO Xuan, GUO Jing, CHEN Ning, MEI Long, ZHENG Tingting, ZHANG Lifang, ZHANG Wei. Discuss the safety management of medical toxic drugs in medical institutions [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 705-708.
[12]	SHA Mingquan, ZHANG Yawei, ZHOU Hongjie, WEN Baoshu. A comparative progress and prospect for drug technological guidances system in China [J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1045-1049.
[13]	SONG Mingyue, ZHANG Ran, WU Zhiang. Influencing factors of quality risk management of drug recall in China [J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1087-1090.
[14]	GENG Kexin, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian, SA Rina, JIANG Hao, ZOU Lina. Safety of traditional Chinese medicine among lactating women and pharmacovigilance [J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 908-912.
[15]	ZHANG Qingxia, JIANG Yongxian, DONG Yuexin, XIAN Ying, YAN Suying. Risk analysis and precautions related to storage conditions specified in package inserts of western medicines in a hospital [J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 913-918.

Guidelines for Good Pharmacoepidemiology Practices

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics